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Serotypes 6A/B, 19F, and 23F accounted for 73% of 140 mucosal isolates
of Streptococcus pneumoniae from Hong Kong. In pulsed-field gel electro-
phoresis analysis, a group of related patterns was shared by 14 of 15 cipro-
floxacin-resistant and 12 of 16 ciprofloxacin-susceptible isolates. These
strains exhibited capsular switching and were highly similar to the Spanish
23F clone.
Streptococcus pneumoniae, the most important cause of
community-acquired pneumonia worldwide, particularly
affects young children, elderly persons with chronic cardio-
pulmonary conditions, and immunosuppressed patients of
all ages. Widespread emergence of antimicrobial resistance
has become a concern in recent years. In many countries,
rates of resistance to penicillin are >40%. Among penicillin-
resistant S. pneumoniae, 60% to 90% are also resistant to the
macrolides, tetracyclines, chloramphenicol, clindamycin, and
cotrimoxazole. For this reason, newer fluoroquinolones with
expanded activity against gram-positive bacteria have been
recommended by the Infectious Disease Society of America
as initial treatment of choice for community-acquired pneu-
monia (1). 
Although resistance to the newer fluoroquinolones
remains rare in most countries, the percentage of nonsuscep-
tible S. pneumoniae has increased from <0.5% for ofloxacin
to 5.5% for levofloxacin (MIC >4 µg/mL) from 1995 to 1998 in
Hong Kong (2). Almost all strains of fluoroquinoline-resis-
tant  S. pneumoniae were isolated from respiratory tract
specimens. Knowledge of the serotype distribution of  S.
pneumoniae, particularly strains with the emerging resis-
tance pattern, is important for development of conjugate vac-
cines. 
We studied the serotype distribution of recent isolates of
drug-resistant pneumococci from Hong Kong, including iso-
lates with resistance to the fluoroquinolones. To understand
better the emergence of fluoroquinolone-resistant S. pneu-
moniae in this locality, we used pulsed-field gel electrophore-
sis (PFGE) to compare strains. 
The Study
We examined sputum isolates of S. pneumoniae obtained
from four regional laboratories in Hong Kong during a pro-
spective regional survey in 1998 (2). The four laboratories
(A-D) provide microbiology service to seven public hospitals,
including a university medical center, four other major medi-
cal centers, and two rehabilitation centers. Together they
served a population of approximately 3 million in the Hong
Kong Island (south and west), Kowloon (central), and the
New Territory (south and north) regions of Hong Kong. 
All strains were nonduplicate isolates obtained from
consecutive clinical samples of hospitalized patients during
the second half of 1998. Of 143 isolates obtained, three
became nonviable during storage. The numbers of isolates
from laboratories A, B, C, and D were 46, 39, 12, and 43,
respectively. 
MICs for penicillin and erythromycin were determined
by the E-test method (AB Biodisk, Solna, Sweden), according
to the manufacturer’s instructions. MICs for ciprofloxacin,
levofloxacin, and trovafloxacin were determined by a stan-
dardized broth microdilution procedure with cation-adjusted
Mueller-Hinton broth supplemented with 2.5% lysed horse
blood (3). All MIC results were interpreted according to
National Committee for Clinical Laboratory Standards. For
ciprofloxacin, an MIC value of  >4 µg/mL was regarded as
resistant (4). The isolates were serotyped by the quellung
reaction (5) with sera of various reactivities (pools A to I, P to
T, and selected major groups and serum factors) from the
Statens Seruminstitut (Copenhagen, Denmark). All 15 cipro-
floxacin-resistant isolates were compared with 16 ciprofloxa-
cin-susceptible isolates, S. pneumoniae ATCC 49619, and the
well-defined Spanish clones of serotypes 23F and 6B (SP264
ATCC 700669 and GM17 ATCC 700670, respectively), by
PFGE after digestion of the genomic DNA with  SmaI and
ApaI, respectively (6).
Ciprofloxacin-susceptible isolates of serotypes 6A, 19F,
and 23F, matching the serotypes in the ciprofloxacin-resis-
tant isolates, were chosen for PFGE analysis. The 16 ciprof-
loxacin-susceptible isolates included the remaining 4 isolates
of serotype 6A and 6 each of serotypes 19F and 23F, chosen
randomly. Of the 16 ciprofloxacin-susceptible isolates, 5 were
penicillin sensitive, 3 were intermediate, and 8 were resis-
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tant. These ciprofloxacin-susceptible isolates were obtained
from all four laboratories (A, 5; B, 4; C, 3; and D, 4). The
Fisher exact or chi-square test was used for statistical analy-
sis, with a value of <0.05 indicating statistical significance.
Of the 140 isolates, 18 (12.9%) and 87 (62.1%) were
intermediate (MIC 0.11 µg/mL) and resistant (MIC  >2 µg/
mL) to penicillin, respectively. One hundred twelve (80%) of
140 were nonsusceptible to erythromycin (MIC >0.5 mg/mL).
Fifteen of the 140 isolates were resistant to ciprofloxacin
(four isolates from laboratory A, one from laboratory B, two
from laboratory C, and eight from laboratory D). The 15 iso-
lates had ciprofloxacin MICs of 4 µg/mL (4/15), 8 mg/mL (2/
15), 16 µg/mL (5/15), and 32 µg/mL (4/15). All nine isolates
with ciprofloxacin MICs 16 to 32 µg/mL and one with a cipro-
floxacin MIC 8 µg/mL were intermediately resistant (2/10) or
resistant (8/10) to levofloxacin. One and three isolates with
ciprofloxacin MICs of 16 and 32 mg/mL, respectively, were
intermediately resistant (1/4) or resistant (3/4) to trovafloxa-
cin. All four trovafloxacin-nonsusceptible isolates were resis-
tant to levofloxacin. All ciprofloxacin-resistant strains were
from adults 54 to 88 years of age and were resistant to both
penicillin and erythromycin. No isolates were obtained from
the children in the 6- to 17-year age group. Penicillin-non-
susceptible strains were common in all other age groups: <2
years (9/11), 2 to 5 years (21/23), 18 to 49 years (9/11), 50 to
64 years (10/11), and >65 years (56/84).
Eighteen serotypes or serogroups were identified among
the 123 typeable strains (Table). The most common sero-
types were 23F (41.4%), 19F (18.6%), and 6B (9.3%). The
combined proportions of these three serotypes by age group
were as follows: <2 years (9/ 11), 2 to 5 years (20/23), 18 to 49
years (9/11), 50 to 64 years (9/11), and  >65 years (50/84).
Penicillin-nonsusceptible strains were more likely than sus-
ceptible ones to belong to these three serotypes (93 of 105 vs.
4 of 35, p<0.001). For the penicillin sensitive, intermediate,
and resistant isolates, 10, 4, and 3 isolates were untypeable,
respectively. Exclusive of the untypeable isolates, 7 (28%) of
25, 13 (92.9%) of 14, and 84 (100%) of 84 of the penicillin-sen-
sitive, intermediate, and resistant isolates, respectively,
were restricted to serogroups 6, 19, and 23. On the basis of
identical serotypes, coverage of the recently licensed hep-
tavalent-conjugated vaccine by age groups was 81.8% for
those <2 years, 91.3% for 2 to 5 years, 81.8% for 18 to 49
years, 81.8% for 50 to 64 years, and 59.5% for >65 years.
PFGE analysis identified seven groups of DNA patterns
when either SmaI or ApaI was used (Figure). The six sub-
types of group A (A0-A5) were either identical (A0) to that of
the Spanish 23F clone or differed from it by 1 to 4 bands (A1
to A5). Group A patterns were shared by 14 of 15 ciprofloxa-
cin-nonsusceptible (all A1) and 12 of 16 ciprofloxacin-suscep-
tible (3 A0, 3 A1, 3 A2, 1 A3, 1 A4, and 1 A5) isolates. The
remaining five distinct profiles (B, C, D, E, F) were identified
in each of the remaining five isolates. All strains with group
A subtypes were either identical or closely related by ApaI
analysis. 
Conclusions
PFGE analysis showed that most ciprofloxacin-resistant
and ciprofloxacin-susceptible  S. pneumoniae isolates were
either identical or closely related to the Spanish 23F clone.
This clone is dominant in Hong Kong, where it accounted for
approximately 70% of all penicillin-resistant S. pneumoniae
isolates from 1994 to 1997 (7). Our data suggest that this
clone has acquired fluoroquinolone resistance and is already
widespread in Hong Kong. In contrast, in Canada and Spain
fluoroquinolone-resistant pneumococci are also emerging,
but with genetically diverse strains (4). Nonetheless, our
finding raises the possibility that this fluoroquinolone-resis-
tant variant of the Spanish 23F clone might spread interna-
tionally, as its ancestor did in the past decade (8). Therefore,
infection control guidelines should be formulated for screen-
ing and isolating patients with fluoroquinolone-resistant S.
pneumoniae. Furthermore, molecular analysis of fluoroqui-
nolone-resistant strains from other countries compared with
those from Hong Kong is also indicated to determine
whether this clone has already disseminated outside Hong
Kong.  
Our data show that the Hong Kong fluoroquinolone-
resistant clone is resistant to multiple other antibiotics,
including penicillin, erythromycin, and clindamycin (2). This
finding implies that the fluoroquinolone-resistant variant
could be selected not only by fluoroquinolones but also by
other antibiotics. In Sweden, for instance, cotrimoxazole has
been shown to select for penicillin resistance in children
attending day-care centers (9). Given the wide range of anti-
biotic classes involved, further emergence of the fluoroqui-
nolone-resistant clone is likely. One potentially sinister
situation would be dissemination of the clone to children.
Although fluoroquinolone is rarely used in children in Hong
Kong, the fluoroquinolone-resistant strain could spread, for
example, through household contacts from adults to chil-
dren. Its spread could readily be facilitated by the frequent
misuse of antibiotics for upper respiratory tract infections in
children. The therapeutic half-life of fluoroquinolones as
treatment for pneumococci is now being challenged. Finally,
three different serotypes (6A, 19F, 23F) were expressed by
our strains that were closely related in the PFGE analysis.
This is likely a result of capsular switching, as reported pre-
viously (10). 
Figure. Pulsed-field gel electrophoresis (PFGE) patterns of  SmaI-
digested genomic DNA of Streptococcus pneumoniae isolates. Seven
distinct patterns, including A and its subtypes (A0 to A5) and B to G,
are shown. Labels indicate the PFGE pattern, hospital source, and
serotype. Lane 1: molecular weight markers; lane 2: S. pneumoniae
ATCC 49619; lanes 3 to 8: ciprofloxacin-resistant isolates; lane 9:
Spanish 23F clone (ATCC 700669); lanes 10-19: ciprofloxacin-sensi-
tive isolates.Dispatches
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In conclusion, most of the drug-resistant pneumococci in
Hong Kong were of serotypes 6A/B, 19F, and 23F. Fluoroqui-
nolone-resistant strains, which were found only in older
adults, were genetically highly similar and probably have
arisen by acquisition of fluoroquinolone resistance by the
locally dominant Spanish 23F clone. 
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Table. Distribution of capsular types in 140 strains of mucosal Streptococcus pneumoniae with respect to age and resistance to ciprofloxacin
Type
Age group (years) Ciprofloxacin 
MIC  >4 µg/mL
No. (%)
<2 2-5 18-49 50-64 >65 Noa (n=125)
No. (%)
Yes (n=15) No. (%)
19F 4 3 1 4 14 19 (15.2) 7 (46.7) 26 (18.6)
23F 4 12 8 4 30 51 (40.8) 7 (46.7) 58 (41.4)
6A 1 1 3 4 (0.8) 1 (6.7) 5 (3.6)
aNumber of strains for other serotype or serogroup by age groups: <2 years (1 for 6B and 1 untypeable), 2 to 5 years (5 for 6B, 1 for 9V, and 1 untypeable), 18 to
49 years (1 for 10B and 1 for 35), 50 to 64 years (1 for 6B, 1 for 19C, and 1 for 34), and >65 years (6 for 6B, 1 for 7F, 1 for 9A/L, 1 for 10C/F, 1 for 11A, 3 for 13,
1 for 15B, 1 for 19B, 1 for 21, 1 for 22A, 5 for 35, and 15 untypeable). No isolates were obtained from the children in the 6- to 17-year age group. All strains with
serotypes or serogroups other than 6A, 19F, and 23F were sensitive to ciprofloxacin.